Atopic Dermatitis: JAK Inhibitors and Beyond (AAN)
Price: FREE for members and non-members
Session recorded on October 19, 2023
Speaker: Clinton P. Dunn, MD
Atopic dermatitis and eczema are often used interchangeably but there are subtle differences between the conditions. In this webinar, Dr. Clint Dunn will give a brief overview of atopic dermatitis and discuss the therapeutic options such as topical therapies, systemic therapies, biologic therapies, and JAK inhibitors.
Viewers can earn credit by completing the post-test questions.
This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network (AAN).
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Allied Health Professionals
Upon completion of this activity learners should be able to:
1. Describe the fundamental features of atopic dermatitis.
2. Explain the treatment options for atopic dermatitis.
3. Identify the ideal patient for each type of therapy.
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.
Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All identified relevant financial relationships with ineligible companies have been mitigated.
Clinton P. Dunn, MD
Speaker, Consultant: ALK
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance